Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.
Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, Rodríguez-Salas N, Burgos E, Ramos D, Calatrava A, Andrada E, Díaz-López E, Sánchez A, Madero R, Cejas P, Feliu J.
Custodio A, et al. Among authors: aparicio j.
Mol Cancer Ther. 2014 Sep;13(9):2226-37. doi: 10.1158/1535-7163.MCT-13-1109. Epub 2014 Jun 30.
Mol Cancer Ther. 2014.
PMID: 24980946